Worldwide strategic alliance for non-chiral chromatography
Novasep and instrAction have entered into an alliance that will offer customers in the pharmaceutical industry a combination of instrAction?s proprietary API-selective stationary phases and Novasep?s purification capabilities and high performance chromatography technologies.
Novasep and instrAction have entered into an alliance that will offer customers in the pharmaceutical industry a combination of instrAction’s proprietary API-selective stationary phases and Novasep’s purification capabilities and high performance chromatography technologies. Together, the companies aim to develop and operate or supply optimized large-scale chromatography processes for purifying synthetic and semi-synthetic compounds.
“With the ever-increasing complexity of pharmaceutical compounds, traditional purification processes including crystallization, and even normal or reversed-phase chromatography, are often too expensive, and, worse, ineffective,” says René De Vaumas, executive vice president in charge of Novasep Synthesis’ business development.
“We believe that together, instrAction and Novasep will develop solutions that will provide great improvement in the purification of a number of pharmaceutical compounds,” said Dr Thomas Schwarz, CEO of instrAction GmbH. “Moreover, we believe that our joint approach with a single point of contact and streamlined project management will help reduce process development timelines.”
For more information on the companies visit their websites at www.novasep.com and www.instraction.com
An LC–HRMS Method for Separation and Identification of Hemoglobin Variant Subunits
March 6th 2025Researchers from Stanford University’s School of Medicine and Stanford Health Care report the development of a liquid chromatography high-resolution mass spectrometry (LC–HRMS) method for identifying hemoglobin (Hb) variants. The method can effectively separate several pairs of normal and variant Hb subunits with mass shifts of less than 1 Da and accurately identify them in intact-protein and top-down analyses.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
